Talk:Tislelizumab

Why avoid binding to Fc gamma receptors

perhaps to reduce side effects seen with other anti-PD-1 mabs ? - need a ref. - Rod57 (talk) 16:32, 7 July 2017 (UTC)

BeiGene say " It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells." [1] - Rod57 (talk) 14:00, 3 January 2018 (UTC)

Recommended updates to Tislelizumab development and clinical trials

DISCLOSURE: I work for Syneos Health, a communications agency that is representing BeiGene, the company developing Tislelizumab.

We would like to recommend factual updates to this page, as there is outdated information about the developer of Tislelizumab and its current clinical trials.

We have created a Sandbox, which contains the most up-to-date factual information about Tislelizumab, all newly referenced. For your consideration, we would like to propose updates to the Tislelizumab Article, based on this Sandbox: https://en.wikipedia.org/wiki/User:Mattsnod/sandbox --Mattsnod (talk) 21:27, 6 July 2020 (UTC)

@Mattsnod:: Thanks - very helpful. The main differences I can see is the new section on Medical uses (I've added that in with minor formatting changes), and that the brief chronological Clinical Trials section is replaced with a full list of the registered trials, with no dates and no reports or results. As a compromise we could add the proposed list to what is there now. ? - Rod57 (talk) 09:30, 22 July 2020 (UTC)

@Rod57:: Thanks for your reply and the thoughful edit. Regarding the Clinical trials section, yes, what's in my sandbox is a list of all known, current clinical trials underway for Tislelizumab. The list was provided by BeiGene but includes references to each trial's page on clinicaltrials.gov. Typically, on clinicaltrials.gov, there is a "Study Results" tab on each trial's page that shows the study results. Here's an example. But for these trials, there are not yet any listed results. Hope that helps, and again, thanks for the work you do as an editor. Mattsnod (talk) 23:01, 24 July 2020 (UTC)

@Rod57:: Hi again. Wanted to check in to see if you had a chance to view the above reply ^. Mattsnod (talk) 21:52, 15 September 2020 (UTC)

Article expansion

This review contains Chemistry, Pharmacodynamics, Pharmacokinetics/Metabolism, Clinical Efficacy, Safety and Tolerability, and Regulatory information. If someone is interested, I think this (and following some citations) could beef up this article. I do not have the time nor particular interest, so I will leave this here. Kimen8 (talk) 01:30, 2 April 2024 (UTC)

Additionally, the results from the "phase II clinical trial for urothelial cancer started in China in 2017" are available, so the History section can be updated. Kimen8 (talk) 01:37, 2 April 2024 (UTC)